Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-27 23:12:07 - browse：2434

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Kristina Burow of ARCH Venture Partners shares her next big bets STAT

leisure time

WSS

Why you get paid to donate plasma but not blood

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

FDA seeking to stop procedures at two unregulated stem cell clinics

RaDonda Vaught to speak at CommonSpirit event on patient safety

How to fix the rural physician shortage in the U.S.

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

entertainment

Wikipedia

hotspot

What does generative AI mean for health care? We asked experts

House looks to weaken Medicare negotiation

Anesthesiologist group: stop taking Ozempic before surgery

What we know about the American soldier detained in North Korea

The cancer drug shortage isn’t new — and neither are the solutions

Flagship, Pfizer team up in deal worth up to $7 billion

Duchenne breakthrough therapy leaves behind pioneering families

ALS groups 'won't be played again' by the FDA, drug sponsors

After affirmative action ruling, medical educators look to 'holistic review'

A Q&A with Aletha Maybank, AMA’s chief health equity officer

focus

How to fix the rural physician shortage in the U.S.

A strong 6.5

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

US soldier in North Korean custody after crossing DMZ line

In search for therapies for solid tumors, companies turn to claudin

Flu vaccine offering decent levels of protection this winter, new data show

explore

entertainment

leisure time

focus